Genentech files vismodegib at FDA for Basal Cell Carcinoma

Genentech/Roche has submitted a new drug application to the FDA for vismodegib as a treatment for patients with advanced, inoperable basal cell carcinoma . The new oral drug is designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90% of basal cell carcinoma cases, the most common type of skin cancer, which is generally curable by surgery.